The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | SKYSCRAPER-08: first-line tiragolumab + atezolizumab in esophageal SCC
Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on the Phase III SKYSCRAPER-08 (NCT04540211) trial, which evaluates the efficacy and safety of tiragolumab (anti-TIGIT) plus atezolizumab (anti-PD-L1) in combination with chemotherapy (CT) as first-line treatment for Asian patients with unresectable locally advanced, unresectable recurrent, or metastatic esophageal squamous cell carcinoma (ESCC). The trial demonstrates significant improvements in both progression-free survival (PFS) and overall survival (OS) for the tiragolumab plus atezolizumab plus CT group compared to the placebo plus CT group. The safety profile is consistent with known risks of individual treatments. This study suggests a promising treatment strategy for ESCC in an Asian population. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
